June 7th, 2009 - 06:52 GMT Interim Analysis of Long-Term Data with ONGLYZA™ (saxagliptin) When Added to Metformin in People with Inadequately Controlled Type 2 Diabetes Present Results from an interim analysis of a long-term Phase 3 study at 102 weeks with ONGLYZA™ (saxagliptin), an investigational, selective, reversible inhi Read more
March 25th, 2008 - 11:35 GMT Sanofi-aventis Supports the ADA Educational Program “Standing Together against Diabetes”
